Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $8.29 Consensus Price Target from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.29.

Several analysts have recently issued reports on the company. HC Wainwright reissued a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a report on Tuesday, October 15th. Canaccord Genuity Group dropped their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, Wells Fargo & Company dropped their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 12th.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in VTYX. Palumbo Wealth Management LLC acquired a new stake in Ventyx Biosciences during the third quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. grew its stake in Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after acquiring an additional 5,310 shares during the period. SG Americas Securities LLC acquired a new stake in Ventyx Biosciences in the second quarter valued at approximately $32,000. The Manufacturers Life Insurance Company grew its stake in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ventyx Biosciences in the second quarter valued at approximately $58,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Price Performance

Shares of NASDAQ VTYX opened at $2.21 on Monday. The stock’s fifty day moving average price is $2.24 and its two-hundred day moving average price is $2.94. Ventyx Biosciences has a one year low of $1.79 and a one year high of $15.81. The firm has a market cap of $156.18 million, a price-to-earnings ratio of -0.81 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. On average, equities analysts anticipate that Ventyx Biosciences will post -2.14 earnings per share for the current fiscal year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.